{"schema_version":"1.0","type":"article","title":"Moderna Surges 176.97% After Its Personalized Cancer Vaccine Clears a Phase 3 Test","url":"https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma-en.md","lang":"en","date":"2026-08-21","publish_at":"2026-08-21T08:00:00+08:00","updated_at":"2026-08-21","category":"商業分析系列","topic":"商業分析系列","tags":["Moderna","Merck","intismeran autogene","INTerpath-001","personalized cancer vaccine","melanoma","mRNA manufacturing","Phase 3"],"summary":"Positive topline results from INTerpath-001 sent Moderna shares up 176.97% in one session. The deeper valuation question is whether patient-specific design, manufacturing, release and clinical delivery can become a scalable platform.","key_points":[],"facts":[],"sections":["01 | What did Phase 3 actually establish?","02 | This is not an off-the-shelf vaccine","03 | Why might this cancer-vaccine approach be different?","04 | Why mRNA? Industrial control over designed variation","05 | The market bought four distinct sources of value","06 | Personalized economics require a different operating report","07 | A 176.97% surge raises the risk as well as the expectations","08 | Taiwan participated, but local beneficiaries should not be invented","Conclusion | Cancer has not said goodbye; the market priced the ability to manage difference","References","Disclaimer"],"references":[{"title":"[Nasdaq: MRNA market data]","source":"","date":"","url":"https://api.nasdaq.com/api/quote/MRNA/info?assetclass=stocks"},{"title":"[Moderna: prespecified interim topline results from Phase 3 INTerpath-001]","source":"","date":"","url":"https://news.modernatx.com/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-plus-keytruda-met-endpoints-of-rfs-and-dmfs-in-melanoma"},{"title":"[Merck: INTerpath-001 met RFS and DMFS endpoints]","source":"","date":"","url":"https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/"},{"title":"[ClinicalTrials.gov: INTerpath-001, NCT05933577]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT05933577"},{"title":"[Merck and Moderna: five-year Phase 2 KEYNOTE-942 follow-up]","source":"","date":"","url":"https://www.merck.com/news/moderna-and-merck-present-5-year-data-for-intismeran-autogene-in-combination-with-keytruda-pembrolizumab-in-patients-with-high-risk-stage-iii-iv-melanoma-following-complete-resection-at-the-20/"},{"title":"[Moderna 2025 Form 10-K]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm"},{"title":"[Merck 2025 Form 10-K]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm"},{"title":"Verification cutoff: August 20, 2026.","source":"","date":"","url":""}],"images":[{"alt":"Figure 1 | INTerpath-001 met the RFS and DMFS endpoints, but hazard ratios, curves, absolute effects and overall-survival evidence remain undisclosed","url":"https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma-en/figure-02.png"},{"alt":"Figure 2 | Each patient's path runs from tumor and blood sampling through sequencing, neoantigen selection, mRNA manufacture, quality release and administration","url":"https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma-en/figure-01.png"},{"alt":"Figure 3 | Commercializing a personalized mRNA medicine requires four connected systems: prediction, manufacturing, patient-level quality release, and cold-chain clinical delivery","url":"https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma-en/figure-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma-en/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-21）。Moderna Surges 176.97% After Its Personalized Cancer Vaccine Clears a Phase 3 Test。https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh":"2026-08-21-moderna-merck-intismeran-phase3-melanoma.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}